QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CYTK

QT66Cytokinetics, Incorporated
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
78.78
+0.67+0.86%
OverviewShort InterestFilings
CYTKQT66Cytokinetics, Incorporated·NASDAQ
OverviewShort InterestFilings
78.78+0.86%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-6.84
Insider Own1.08%
Shs Outstand135.58M
Perf Week13.73%
Market Cap9.72BForward P/E-EPS next Y-4.65Insider Trans0.11%Shs Float-Perf Month3.05%
Enterprise Value10.88BPEG0.43EPS next Q-1.64Inst Own-Short Float-Perf Quarter25.15%
Income-837817593.00P/S91.85EPS this Y6.62%Inst Trans-Short Ratio-Perf Half Y27.02%
Sales105.81MP/B-EPS next Y27.19%ROA-65.15%Short Interest-Perf YTD23.98%
Book/sh-6.10P/C-EPS next 5Y-ROE139.66%52W High80.20 -1.77%Perf Year142.10%
Cash/sh6.04P/FCF-EPS past 3/5Y-ROIC-56.16%52W Low31.99 146.26%Perf 3Y-
Dividend Est.-EV/EBITDA-14.81Sales past 3/5Y-2.52% 9.46%Gross Margin90.34%Volatility2.95% 2.71%Perf 5Y-
Dividend TTM-EV/Sales102.81EPS Y/Y TTM-10.84%Oper. Margin-605.06%ATR (14)3.27Perf 10Y-
Dividend Ex-Date-Quick Ratio4.21Sales Y/Y TTM488.89%Profit Margin-784.02%RSI (14)63.85Recom2.11
Dividend Gr. 3/5Y-Current Ratio4.21EPS Q/Q-22.79%SMA207.37%Beta0.79Target Price101.31
Payout0.00%Debt/Eq-1.56Sales Q/Q850.00%SMA5011.07%Rel Volume1.40Prev Close78.11
Employees498LT Debt/Eq-1.85EarningsAug 06SMA20023.64%Avg Volume2.53MPrice78.78
IPO DateApr 30, 2004Option/ShortYes / YesEPS/Sales Surpr.0.00% 111.11%Net Debt/EBITDA-1.58Volume3,547,447Change0.86%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-17-26ReiteratedRBC CapitalOutperform$101 → $119
May-11-26ReiteratedH.C. WainwrightBuy$136 → $140
May-06-26ReiteratedUBSNeutral$101 → $119
May-06-26ReiteratedStifel Nicolaus$98 → $108
May-06-26ReiteratedMorgan StanleyOverweight$90 → $103
May-05-26ReiteratedTruist Financial$92 → $106
Apr-10-26InitiatedWells FargoOverweight$95
Mar-10-26ReiteratedRobert W. Baird$84
Mar-06-26ReiteratedUBSNeutral$61 → $69
Feb-20-26ReiteratedRBC CapitalOutperform$95 → $101
Latest News
Jun-17-26
Jun-17-2608:00PM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo
02:54PM
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?Yahoo
04:48AM
Needham Reiterates Buy on Cytokinetics, Maintains $102 Price TargetBenzinga
Jun-16-26
Jun-16-2601:29PM
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?Yahoo
Jun-13-26
Jun-13-2607:34PM
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM TreatmentYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1068818
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1010339
Gross Profit9578-321
Selling, General and Administrative Excl. Other332284215
Research and Development410406339
Other Operating Expense-60-339
Operating Income-641-612-536
Interest Expense11310487
Unusual Expense
———
Non-Operating Income (Expense)106173-33
Net Income Before Taxes-829-785-590
Income Taxes
000
Consolidated Net Income-829-785-590
Net Income From Continuing Operations-829-785-590
Net Income-829-785-590
EPS (Recurring)-6.83-6.54-5.26
EPS (Basic, Before Extraordinaries)-6.83-6.54-5.26
EPS (Diluted)-6.84-6.54-5.26
EBITDA-734-775-493
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio91.4186.65—
Gross Margin89.6288.64-1,783.33
Operating Margin-604.72-695.45-2,977.78
Net Margin-782.08-892.05-3,277.78
Shares Outstanding123120112
Market Capitalization9,6907,625—
Operating Lease Expense
———
Insider Trading Volume
$83.02$73.86$64.69$55.53$46.36● Close Price0.00M1.95M3.91M5.86M7.82MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Blum Robert IPresident & CEOJun 15 '26Sale70.467,500528,450385,330Jun 15 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentJun 09 '26Option Exercise7.807,00054,600157,402Jun 09 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentJun 09 '26Sale67.983,500237,930153,902Jun 09 12:00 AM
Callos AndrewEVP, Chief Commercial OfficerJun 01 '26Option Exercise23.2630,000697,80073,555Jun 01 12:00 AM
PARSHALL B LYNNEDirectorJun 01 '26Sale74.085,000370,40015,784Jun 01 12:00 AM
Kaye Edward M. MDDirectorJun 01 '26Sale76.092,933223,17210,283Jun 01 12:00 AM
Callos AndrewEVP, Chief Commercial OfficerJun 01 '26Sale74.0815,0001,111,20058,555Jun 01 12:00 AM
Blum Robert IPresident & CEOMay 27 '26Sale77.217,500579,075392,830May 28 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentMay 19 '26Option Exercise7.807,00054,600157,402May 20 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentMay 19 '26Sale75.693,500264,915153,902May 20 12:00 AM
Blum Robert IPresident & CEOMay 14 '26Sale77.927,500584,400400,330May 14 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentMay 05 '26Option Exercise7.807,00054,600157,402May 05 12:00 AM
Malik Fady IbrahamEVP Research & DevelopmentMay 05 '26Sale77.373,500270,795153,902May 05 12:00 AM
WIERENGA WENDELLDirectorMay 05 '26Option Exercise12.408,06499,99436,669May 05 12:00 AM
WIERENGA WENDELLDirectorMay 05 '26Sale75.004,032302,40032,637May 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR